Drugs / OsrhAAT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05315921 | Mar 2022 → Mar 2023 | alpha 1-antitrypsin deficiency | Healthgen Biotechnology Corp. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OsrhAAT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05315921 ↗ |
| Route | Intravenous | “OsrhAAT 1 mg/kg IV infusion” NCT05315921 ↗ |